The Week in Review: China’s 12th Five-year Plan for Medical Technology

China released its 12th Five-year Plan for Medical Technology, setting a long list of broad goals to be accomplished by the end of 2015; the World Health Organization certified the quality of the SFDA’s vaccine supervision, opening a huge market for vaccine makers; China wants to increase the benefits of its healthcare reform for citizens; Huahai Pharma will raise as much as $204 million through a private placement; Regeneron and Bayer have begun a China Phase III trial of their treatment for wet AMD; Ascletis was nominated for InVivo’s Exit/Financing Deal of the Year award; Sihuan Bioengineering is suing Vitapharm Technology of Australia over a patent dispute; Haibin Pharma received a EU-GMP certificate from Germany for meropenem bulk drug; and LDR was granted SFDA approval to market two spinal device systems. More details…. Stock Symbols: (SHA: 600521) (NSDQ: REGN) (XETRA: BAY) (SHE: 000518) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});